ExhibitsMatters Affecting Comparability (Exhibit A)
Non-GAAP Financial Measures (Exhibit B)
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology, critical care, and hemostasis.
Talecris Biotherapeutics Holdings Corp.Consolidated Income Statements(in thousands, except per share amounts)(Unaudited) Three Months Ended March 31, 20112010Net revenue:Product$ 398,980$ 374,615Other7,6836,346Total406,663380,961Cost of goods sold233,619217,351Gross profit173,044163,610Operating expenses:Selling, general, and administrative62,71767,620Research and development16,53216,271Total79,24983,891Income from operations93,79579,719Other non-operating (expense) income:Interest expense, net(10,750)(11,263)Equity in earnings of affiliate151147Total(10,599)(11,116)Income before income taxes83,19668,603Provision for income taxes(27,739)(23,264)Net income$
45,339Net income per common share:Basic$
.35Talecris Biotherapeutics Holdings Corp.Consolidated Balance Sheets(in thousands, except share and per share amounts) (Unaudited)March 31,December 31,20112010AssetsCurrent assets:Cash and cash equi
|SOURCE Talecris Biotherapeutics Holdings Corp.|
Copyright©2010 PR Newswire.
All rights reserved